[Cynthia]

Debbie,

I do not believe that any of the participants in the study were Her2 negative. (I believe the article is a bit confusing on this point.) The distinction is among the Her2+++ and Her2+ and Her2++. The surprise here is how effective the vaccine appears to be in the Her2+ and Her2++ population, a group not currently receiving Herceptin.

The control arm was also made up of all Her2 positive patients who received no vaccine.

Given the small size of the trial, we can't draw too many conclusions, though the numbers and trends are large enough to show promise as the vaccicne heads into the Phase III.

By way of disclaimer, I was in this trial as one of the Her2+++ who did receive the vaccine (which was then known as the E75 vaccine).

Best regards,